TARSUS PHARMACEUTICALS, INC. Equity Securities, FV-NI, Cost
TARSUS PHARMACEUTICALS, INC. (TARS) had Equity Securities, FV-NI, Cost of $1.11 million as of 2023-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:EquitySecuritiesFvNiCost · last filed 2025-02-25
- 2023-12-31: Equity Securities, FV-NI, Cost $1.11M.
- 2023-09-30: Equity Securities, FV-NI, Cost $1.11M.
- 2023-06-30: Equity Securities, FV-NI, Cost $1.11M.
- 2023-03-31: Equity Securities, FV-NI, Cost $1.23M.
| Period end | Equity Securities, FV-NI, Cost | Equity Securities, FV-NI, Cost as first filed |
|---|---|---|
| 2023-12-31 | $1.11M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $1.11M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $1.11M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $1.23M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $1.23M 10-K · filed 2024-02-27 | $639.00K 10-K · filed 2023-03-17 |
| 2022-09-30 | $483.00K 10-Q · filed 2022-11-09 | |
| 2021-12-31 | $1.07M 10-K · filed 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |